

## DEPARTMENT OF HEALTH

NO. R. 885

14 AUGUST 2020

**MEDICINES AND RELATED SUBSTANCES ACT, (ACT NO. 101 OF 1965)**  
**(ANNUAL SINGLE EXIT PRICE ADJUSTMENT (SEPA) OF MEDICINES AND**  
**SCHEDULED SUBSTANCES FOR THE YEAR 2021)**

In terms of Regulation 8 (1) of the Regulations Relating to the Transparent Pricing System for Medicines and Scheduled Substances of the Medicines and Related Substances Act, 1965 (No. 101 of 1965) as amended, the Minister of Health is required to determine on an annual basis, the extent to which medicine prices may be adjusted. In making this determination the Minister considers the following provisions of Regulation 8 (1)-

- (a) the average CPI for the preceding year;
- (b) the average PPI for the preceding year;
- (c) changes in the rates of foreign exchange and purchasing power parity;
- (d) international pricing information relating to medicines and scheduled substances;
- (e) comments received from interested persons in terms of regulation 8(2); and
- (f) the need to ensure the availability, affordability and quality of medicines and scheduled substances in the Republic.

Comments received from the annual review in 2019 on the adjustment methodology have indicated that stakeholders would like to have a 100% CPI weighting.


The Pricing Committee in its recommendation for the next annual adjustment cycle may consider this weighting *in addition* to the provisions of Regulation 8(1) as listed above.

The official data to be used with respect to the Consumer Price Index (CPI) for South Africa and the foreign exchange rates would be obtained from official publications by the Statistics South Africa at [www.statssa.gov.za](http://www.statssa.gov.za) and the South African Reserve Bank at [www.resbank.co.za](http://www.resbank.co.za) respectively.

Interested persons are invited to submit any substantiated comments in writing, both on a compact disc and a hard copy within three months from the date of publication of this Notice to:

**The Director-General: Health**  
**For Attention: Director (Pharmaceutical Economic Evaluations)**  
**Room 2611 South Tower**  
**Civitas Building**  
**Corner Thabo Sehume & Struben Streets**  
**PRETORIA, 0001**

For any further enquiries please contact Ms NM Mpanza at the Directorate: Pharmaceutical Economic Evaluations: telephone: 012 395 8209/8181/4/5; e-mail: [sepupdates@health.gov.za](mailto:sepupdates@health.gov.za) or [Ntobeko.Mpanza@health.gov.za](mailto:Ntobeko.Mpanza@health.gov.za)



**DR Z L MKHIZE, MP**  
**MINISTER OF HEALTH**

**DATE:** 08/05/2020